m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03413)
Name
CRx-191
Status
Discontinued in Phase 2
TTD Drug ID
D0VA2I
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Interferon-gamma (IFNG)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interferon-gamma (IFNG) is a therapeutic target for CRx-191. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CRx-191 through regulating the expression of Interferon-gamma (IFNG). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Interferon-gamma (IFNG) is a therapeutic target for CRx-191. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CRx-191 through regulating the expression of Interferon-gamma (IFNG). [1], [2]
Tumor necrosis factor (TNF)
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for CRx-191. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CRx-191 through regulating the expression of Tumor necrosis factor (TNF). [3], [4]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for CRx-191. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CRx-191 through regulating the expression of Tumor necrosis factor (TNF). [4], [5]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for CRx-191. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CRx-191 through regulating the expression of Tumor necrosis factor (TNF). [4], [6]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for CRx-191. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CRx-191 through regulating the expression of Tumor necrosis factor (TNF). [4], [6]
YTH domain-containing family protein 3 (YTHDF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Tumor necrosis factor (TNF) is a therapeutic target for CRx-191. The YTH domain-containing family protein 3 (YTHDF3) has potential in affecting the response of CRx-191 through regulating the expression of Tumor necrosis factor (TNF). [3], [4]
References
Ref 1 m(6) A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020 Oct 15;39(20):e104514. doi: 10.15252/embj.2020104514. Epub 2020 Sep 23.
Ref 2 Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59. doi: 10.1517/14728214.12.1.49.
Ref 3 N6-methyladenosine reader YTH N6-methyladenosine RNA binding protein 3 or insulin like growth factor 2 mRNA binding protein 2 knockdown protects human bronchial epithelial cells from hypoxia/reoxygenation injury by inactivating p38 MAPK, AKT, ERK1/2, and NF-KappaB pathways. Bioengineered. 2022 May;13(5):11973-11986. doi: 10.1080/21655979.2021.1999550.
Ref 4 AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel antioxidant and anti-inflammatory compound: cellular and biochemical characterization of antioxidant activity and inhibition of redox-sensitive inflammatory gene expression. J Pharmacol Exp Ther. 2005 May;313(2):492-501. doi: 10.1124/jpet.104.080804. Epub 2005 Feb 8.
Ref 5 METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of Alpha-klotho. Mol Med. 2021 Sep 9;27(1):106. doi: 10.1186/s10020-021-00365-5.
Ref 6 Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m(6)A modification. Bone. 2022 Jan;154:116182. doi: 10.1016/j.bone.2021.116182. Epub 2021 Sep 13.